The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

New research suggests that it could be possible to separate treatment from hallucinations when developing new drugs based on ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...